期刊
PATHOLOGY
卷 53, 期 3, 页码 339-348出版社
ELSEVIER
DOI: 10.1016/j.pathol.2021.01.003
关键词
Myeloproliferative neoplasms; diagnosis; prognosis; PCR; mutations
类别
Myeloproliferative neoplasms are characterized by somatic mutations in pathways regulating cell proliferation, epigenetic modifications, RNA splicing, or DNA repair. Assessment of mutational profile aids in diagnosis, classification, prognosis evaluation, and guiding targeted therapy. Massively parallel sequencing, especially disease-specific next generation sequencing panels, is the most effective way to provide information on various genetic variants.
Myeloproliferative neoplasms are characterised by somatic mutations in pathways that regulate cell proliferation, epigenetic modifications, RNA splicing or DNA repair. Assessment of the mutational profile assists diagnosis and classification, but also aids assessment of prognosis, and may guide the use of emerging targeted therapies. The most practical way to provide information on numerous genetic variants is by using massively parallel sequencing, commonly in the form of disease specific next generation sequencing (NGS) panels. This review summarises the diagnostic and prognostic value of somatic mutation testing in Philadelphia-negative myeloproliferative neoplasms: polycythaemia vera, essential thrombocythaemia, primary myelofibrosis, chronic neutrophilic leukaemia, systemic mastocytosis, and chronic eosinophilic leukaemia. NGS panel testing is increasing in routine practice and promises to improve the accuracy and efficiency of pathological diagnosis and prognosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据